Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Affiliation
CR-UK Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, UK. jvarley@picr.man.ac.ukIssue Date
2003
Metadata
Show full item recordAbstract
Germline mutations in the human checkpoint gene, hCHK2, were first identified in 1999 in cases of Li-Fraumeni syndrome. Recent studies have demonstrated that the hCHK2 1100delC mutation acts as a low-penetrance tumour suppressor gene in familial breast cancer not associated with mutations in BRCA1 or BRCA2. The present article describes the published studies on hCHK2 1100delC and addresses some of the key questions raised.Citation
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. 2003, 5 (3):123-5 Breast Cancer Res.Journal
Breast Cancer ResearchDOI
10.1186/bcr582PubMed ID
12793891Type
ArticleLanguage
enISSN
1465-542Xae974a485f413a2113503eed53cd6c53
10.1186/bcr582
Scopus Count
Collections
Related articles
- Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
- Authors: Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium
- Issue date: 2002 May
- [CHEK2 and breast cancer risk].
- Authors: Coupier I, Stoppa-Lyonnet D
- Issue date: 2002 Nov
- TP53, hChk2, and the Li-Fraumeni syndrome.
- Authors: Varley J
- Issue date: 2003
- CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
- Authors: Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG
- Issue date: 2008 Feb 1
- The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
- Authors: Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P
- Issue date: 2003 Dec 1